In the ASPSCR1-TFE3 fusion there is preservation of the DNA binding and transcriptional activation domains of TFE3, which is hypothesised to be the oncogenic driver of ASPS through ubiquitous and high-level expression of its fusion partner ASPSCR1 (130). Here, ASPSCR1 is linked to alveolar soft part sarcoma.